In this issue:
- Access to and timing of lung cancer care
- ACT-NOW: chemotherapy use and outcomes in NSCLC
- Lung cancer screening in routine practice
- Cancer risk after smoking cessation
- Link between CVD and lung cancer
- Brigatinib vs alectinib in ALK-positive NSCLC
- Selpercatinib in RET fusion-positive NSCLC
- Osimertinib ± chemotherapy in EGFR-mutated NSCLC
- Neoadjuvant immunotherapy in NSCLC
Please login below to download this issue (PDF)